Company profile: OmniAb
1.1 - Company Overview
Company description
- Provider of antibody discovery technologies for next-generation therapeutics, offering the OmniAb Discovery Platform with diverse antibody repertoires and high-throughput screening via proprietary transgenic animals. Platforms include OmniRat, OmniMouse, and OmniChicken for fully human antibodies, and OmniFlic and OmniClic for bispecific antibodies using a common light chain.
Products and services
- OmniAb Discovery Platform: Delivers access to diverse antibody repertoires and high-throughput screening technologies to enable discovery of next-generation therapeutics using proprietary transgenic animals
- OmniChicken: A transgenic chicken platform that generates human antibodies with robust immune repertoires and high-affinity binding
- OmniRat: A transgenic rat platform that generates fully human antibodies for therapeutic development and discovery of next-generation therapeutics
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to OmniAb
Comecer
HQ: Italy
Website
- Description: Provider of protection technologies in nuclear medicine, isolation, and nuclear power plant equipment, and of screening systems for special applications serving hospitals, universities, industrial groups, and research organizations. Products include aseptic processing and containment systems, a Terbium-161 production line, the IRIS radiopharmaceutical injection system, THERABED protected admission management, ISP radioactive waste management, and dose calibrators.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Comecer company profile →
BioLegend
HQ: United States
Website
- Description: Provider of immunological reagents for biomedical research, developing antibodies, recombinant proteins, bioassays, and other research reagents at a state-of-the-art facility in San Diego, California.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioLegend company profile →
Genemed Biotechnologies
HQ: United States
Website
- Description: Provider of products aimed at improving the role of surgical pathology and personalized medicine, incorporating quality throughout.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Genemed Biotechnologies company profile →
Phenocell
HQ: France
Website
- Description: Provider of iPSC-derived cell models and R&D outsourcing for pharmaceutical, drug discovery, ophthalmology, dermatology, and dermo-cosmetic applications, including retinal pigment epithelial cells for retinal disorder research, a Dry AMD drug discovery platform, sebocytes for acne/hyperseborrhea, melanocytes for pigmentation, and high-throughput screening and custom bioassays with high genomic stability and reproducibility.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Phenocell company profile →
BennuBio
HQ: United States
Website
- Description: Provider of flow cytometry instruments and services that analyze samples regardless of particle size or volume. Offers the Velocyt, a rapid large-particle flow cytometer that returns intact samples; high-throughput intact spheroid and organoid analysis; and 3D cell culture-based drug discovery services that better mimic in vivo conditions, reducing the need for animal studies and improving drug efficacy assessment.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BennuBio company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for OmniAb
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to OmniAb
2.2 - Growth funds investing in similar companies to OmniAb
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for OmniAb
4.2 - Public trading comparable groups for OmniAb
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →